Clinical Trial Update: QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

View source ↗

Summary

A post-marketing surveillance study of the saxagliptin/dapagliflozin fixed-dose combination (QTERN) in Type 2 Diabetes Mellitus has completed, providing regulat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• QTERN (saxagliptin and dapagliflozin)
• Saxagliptin (saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Status: COMPLETED